Cargando…
Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their c...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468804/ https://www.ncbi.nlm.nih.gov/pubmed/34573011 http://dx.doi.org/10.3390/antiox10091379 |
_version_ | 1784573766178701312 |
---|---|
author | Lambadiari, Vaia Thymis, John Kouretas, Dimitris Skaperda, Zoi Tekos, Fotios Kousathana, Foteini Kountouri, Aikaterini Balampanis, Konstantinos Parissis, John Andreadou, Ioanna Tsoumani, Maria Chania, Christina Katogiannis, Konstantinos Dimitriadis, George Bamias, Aristotelis Ikonomidis, Ignatios |
author_facet | Lambadiari, Vaia Thymis, John Kouretas, Dimitris Skaperda, Zoi Tekos, Fotios Kousathana, Foteini Kountouri, Aikaterini Balampanis, Konstantinos Parissis, John Andreadou, Ioanna Tsoumani, Maria Chania, Christina Katogiannis, Konstantinos Dimitriadis, George Bamias, Aristotelis Ikonomidis, Ignatios |
author_sort | Lambadiari, Vaia |
collection | PubMed |
description | Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their combination on levels of oxidant and antioxidant biomarkers. We recruited a total of 160 type 2 diabetics, who received insulin (n = 40), liraglutide (n = 40), empagliflozin (n = 40), or their combination (GLP-1RA+SGLT-2i) (n = 40). We measured at baseline, at 4 and at 12 months of treatment: (a) Thiobarbituric Acid Reactive Substances (TBARS), (b) Malondialdehyde (MDA), (c) Reducing Power (RP), (d) 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS) and (e) Total Antioxidant Capacity TAC). Dual treatment resulted in significant improvement of TBARS, MDA, and ABTS at four months compared with the other groups (p < 0.05 for all comparisons). At twelve months, all participants improved TBARS, MDA, and ABTS (p < 0.05). At 12 months, GLP1-RA and GLP-1RA+SGLT2-i provided a greater reduction of TBARS (−8.76% and −9.83%) compared with insulin or SGLT2i (−0.5% and 3.22%), (p < 0.05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater reduction of MDA (−30.15% and −31.44%) compared with insulin or SGLT2i (4.72% and −3.74%), (p < 0.05). SGLT2i and GLP-1RA+SGLT2-i showed increase of ABTS (12.87% and 14.13%) compared with insulin or GLP1-RA (2.44% and −3.44%), (p < 0.05). Only combined treatment resulted in increase of TAC compared with the other groups after 12 months of treatment (p < 0.05).12-month treatment with GLP1-RA and SGLT2i resulted in reduction of biomarkers responsible for oxidative modifications and increase of antioxidant biomarker, respectively. The combination treatment was superior and additive to each separate agent and also the beneficial effects appeared earlier. |
format | Online Article Text |
id | pubmed-8468804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84688042021-09-27 Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes Lambadiari, Vaia Thymis, John Kouretas, Dimitris Skaperda, Zoi Tekos, Fotios Kousathana, Foteini Kountouri, Aikaterini Balampanis, Konstantinos Parissis, John Andreadou, Ioanna Tsoumani, Maria Chania, Christina Katogiannis, Konstantinos Dimitriadis, George Bamias, Aristotelis Ikonomidis, Ignatios Antioxidants (Basel) Article Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their combination on levels of oxidant and antioxidant biomarkers. We recruited a total of 160 type 2 diabetics, who received insulin (n = 40), liraglutide (n = 40), empagliflozin (n = 40), or their combination (GLP-1RA+SGLT-2i) (n = 40). We measured at baseline, at 4 and at 12 months of treatment: (a) Thiobarbituric Acid Reactive Substances (TBARS), (b) Malondialdehyde (MDA), (c) Reducing Power (RP), (d) 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS) and (e) Total Antioxidant Capacity TAC). Dual treatment resulted in significant improvement of TBARS, MDA, and ABTS at four months compared with the other groups (p < 0.05 for all comparisons). At twelve months, all participants improved TBARS, MDA, and ABTS (p < 0.05). At 12 months, GLP1-RA and GLP-1RA+SGLT2-i provided a greater reduction of TBARS (−8.76% and −9.83%) compared with insulin or SGLT2i (−0.5% and 3.22%), (p < 0.05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater reduction of MDA (−30.15% and −31.44%) compared with insulin or SGLT2i (4.72% and −3.74%), (p < 0.05). SGLT2i and GLP-1RA+SGLT2-i showed increase of ABTS (12.87% and 14.13%) compared with insulin or GLP1-RA (2.44% and −3.44%), (p < 0.05). Only combined treatment resulted in increase of TAC compared with the other groups after 12 months of treatment (p < 0.05).12-month treatment with GLP1-RA and SGLT2i resulted in reduction of biomarkers responsible for oxidative modifications and increase of antioxidant biomarker, respectively. The combination treatment was superior and additive to each separate agent and also the beneficial effects appeared earlier. MDPI 2021-08-28 /pmc/articles/PMC8468804/ /pubmed/34573011 http://dx.doi.org/10.3390/antiox10091379 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lambadiari, Vaia Thymis, John Kouretas, Dimitris Skaperda, Zoi Tekos, Fotios Kousathana, Foteini Kountouri, Aikaterini Balampanis, Konstantinos Parissis, John Andreadou, Ioanna Tsoumani, Maria Chania, Christina Katogiannis, Konstantinos Dimitriadis, George Bamias, Aristotelis Ikonomidis, Ignatios Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
title | Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
title_full | Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
title_fullStr | Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
title_full_unstemmed | Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
title_short | Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
title_sort | effects of a 12-month treatment with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on oxidant and antioxidant biomarkers in patients with type 2 diabetes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468804/ https://www.ncbi.nlm.nih.gov/pubmed/34573011 http://dx.doi.org/10.3390/antiox10091379 |
work_keys_str_mv | AT lambadiarivaia effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT thymisjohn effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT kouretasdimitris effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT skaperdazoi effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT tekosfotios effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT kousathanafoteini effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT kountouriaikaterini effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT balampaniskonstantinos effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT parissisjohn effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT andreadouioanna effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT tsoumanimaria effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT chaniachristina effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT katogianniskonstantinos effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT dimitriadisgeorge effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT bamiasaristotelis effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT ikonomidisignatios effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes |